UNAIDS Pushes for Trump Deal to Revive HIV Fight

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S. President Trump involving Gilead's drug lenacapavir to fight HIV. The proposal aims to revitalize efforts to end AIDS, create jobs, and save lives in poorer nations.

Winnie Byanyima, the executive director of UNAIDS, highlighted the dire consequences of the diminished American financial support in the global battle against HIV, terming it "devastating." She warned that this could lead to countless lives lost among the world's most vulnerable populations.

In Geneva, Byanyima extended a proposal to U.S. President Donald Trump, suggesting that he enable Gilead, a U.S. company, to produce and distribute its HIV prevention drug lenacapavir. The drug, known for its effectiveness in preventing HIV through semi-annual injections, could mark a new era in AIDS prevention if widely distributed.

Byanyima stressed the potential benefits for both U.S. economic interests and the lives of millions in resource-scarce countries. Continuing funding challenges loom as European donors redirect funds, and the U.S. government remains non-committal. Byanyima urged innovative approaches and greater self-sufficiency among African nations.

(With inputs from agencies.)